scholarly article | Q13442814 |
P356 | DOI | 10.1097/00002030-200211080-00006 |
P698 | PubMed publication ID | 12409735 |
P50 | author | Dietmar Fuchs | Q38801487 |
Lars Hagberg | Q97650293 | ||
Bo Svennerholm | Q124366846 | ||
P2093 | author name string | Magnus Gisslén | |
Sahra Abdulle | |||
P433 | issue | 16 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | anti-retroviral agent | Q50430310 |
P304 | page(s) | 2145-2149 | |
P577 | publication date | 2002-11-01 | |
P1433 | published in | AIDS | Q4651863 |
P1476 | title | Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection | |
P478 | volume | 16 |
Q37066982 | Antiretroviral therapy and central nervous system HIV type 1 infection |
Q37073672 | Biomarkers of HIV related central nervous system disease |
Q41070059 | Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients |
Q38597765 | CNS reservoirs for HIV: implications for eradication |
Q47894419 | CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study |
Q24814874 | Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment |
Q33237758 | Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study |
Q82029827 | Cerebrospinal fluid markers in central nervous system HIV infection and AIDS dementia complex |
Q36854127 | Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy |
Q33933507 | Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection |
Q38551796 | Compartmentalized intrathecal immunoglobulin synthesis during HIV infection - a model of chronic CNS inflammation? |
Q37015519 | Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers |
Q99713341 | Effect of Opioid Use on Immune Activation and HIV Persistence on ART |
Q46812278 | Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy |
Q34699119 | Impact of antiretroviral therapy on HIV-related brain injury |
Q88753335 | Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism |
Q36250020 | Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-naïve HIV-infected Thais |
Q35052651 | Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study |
Q35154529 | Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders |
Q38575775 | Neopterin in Diagnosis and Monitoring of Infectious Diseases |
Q37089861 | NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS. |
Q33257724 | Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report |
Q37066971 | Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy |
Q38247035 | Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system |
Q42208551 | Prevalence and predictors of blood-brain barrier damage in the HAART era. |
Q34678105 | Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection |
Q46820459 | Temporarily controlled HIV-1 replication after intravenous immunoglobulin treatment of Guillain-Barré syndrome. |
Q34718135 | Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-a |
Q37372353 | Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment Among HIV-infected Individuals |
Search more.